Skip to main content

GETEC acquires Infrapark Baselland

| News

GETEC acquires Infrapark Baselland

20.11.2018

The energy services provider GETEC is acquiring Infrapark Baselland AG and its activities from the chemicals company Clariant. GETEC also intends to acquire Novartis’s facilities in the neighbouring Schweizerhalle, thus boosting the site’s attractiveness.

Clariant, Infrapark Baselland AG and GETEC recently signed the agreement for the planned sale to GETEC, announced a statement from Infrapark Baselland AG. According to the terms, the transaction will be completed by the end of the year.

GETEC is also acquiring Novartis’s production and infrastructure facilities in the Schweizerhalle site. The move signals the creation of a “new and diversified industrial park with economic significance for the entire region”, writes the statement.

“We are very pleased to have found in GETEC an owner for Infrapark Baselland AG, which has the necessary know-how to operate, integrate and develop industrial parks. I am convinced that this step will give the Schweizerhalle location and thus the employees an attractive future perspective,” commented Oliver Kinkel, head of region Europe at Clariant, in the statement.

With GETEC as operator, Schweizerhalle will gain competitiveness as a chemical life science park and create better growth opportunities “for new companies operating on the site”. A first company has already signed to move into the Schweizerhalle in the coming year: the chemicals specialist Van Baerle. Following the sale, Clariant will also remain as a tenant in Infrapark Baselland.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.